Aquipta Dosage/Direction for Use

Posology: The recommended dose is 60 mg atogepant once daily.
The tablets can be taken with or without meals.
Missed dose: A missed dose should be taken as soon as it is remembered. If it is forgotten for an entire day, the missed dose should be skipped and the next dose taken as scheduled.
Dose modifications: Dosing modifications for concomitant use of specific medicinal products are provided in Table 3 (see Interactions). (See Table 3.)

Click on icon to see table/diagram/image

Special populations: Elderly: Population pharmacokinetic modelling suggests no clinically significant pharmacokinetic differences between elderly and younger subjects. No dose adjustment is needed in elderly patients.
Renal impairment: No dose adjustment is recommended for patients with mild or moderate renal impairment (see Pharmacology: Pharmacokinetics under Actions). In patients with severe renal impairment (creatinine clearance [CLcr] 15-29 mL/min), and in patients with end-stage renal disease (ESRD) (CLcr < 15 mL/min), the recommended dose is 10 mg once daily. For patients with ESRD undergoing intermittent dialysis, AQUIPTA should preferably be taken after dialysis.
Hepatic impairment: No dose adjustment is recommended for patients with mild or moderate hepatic impairment (see Pharmacology: Pharmacokinetics under Actions). Atogepant should be avoided in patients with severe hepatic impairment.
Paediatric population: The safety and efficacy of atogepant in children (< 18 years of age) have not yet been established. No data are available.
Method of administration: AQUIPTA is for oral use. Tablets should be swallowed whole and should not be split, crushed, or chewed.